Quince Therapeutics
QNCX
58 hedge funds and large institutions have $12.4M invested in Quince Therapeutics in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 17 closing their positions.
0.07% less ownership
Funds ownership: 0.19% → 0.13% (-0.07%)
10% less call options, than puts
Call options by funds: $361K | Put options by funds: $403K
12% less funds holding
Funds holding: 66 → 58 (-8)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
52% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 25
52% less capital invested
Capital invested by funds: $26M → $12.4M (-$13.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$931K |
| 2 |
Millennium Management
New York
|
+$214K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$209K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$160K |
| 5 |
Renaissance Technologies
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$2.32M |
| 2 |
D.E. Shaw & Co
New York
|
-$705K |
| 3 |
JP Morgan Chase
New York
|
-$636K |
| 4 |
Morgan Stanley
New York
|
-$587K |
| 5 |
ECM
Evolution Capital Management
Crystal Bay,
Nevada
|
-$393K |
QNCX Hedge Fund Activity: Q3 2022 in Review
58 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q3 2022, worth a combined $12.4M — down 52% from $26M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of QNCX and 9 opened new positions — a net loss of 8 holders — while 25 trimmed existing stakes and 12 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $931K. The largest seller was EPIQ Capital Group, cutting an estimated $2.32M.
- 58 institutional investors held Quince Therapeutics (QNCX) as of Q3 2022, down from 66 in Q2 2022.
- Funds reported $12.4M of Quince Therapeutics stock for Q3 2022, down 52% quarter-over-quarter.
- 9 funds opened new Quince Therapeutics positions in Q3 2022 and 17 closed out, a net change of -8 holders.
- The largest Quince Therapeutics buyer in Q3 2022 was Jacobs Levy Equity Management, an estimated $931K added.
- The largest Quince Therapeutics seller in Q3 2022 was EPIQ Capital Group, an estimated $2.32M sold.
Based on aggregated 13F filings for Q3 2022.